2 documents found, page 1 of 1
Predictive Factors for PCR and Relapse Following Neoadjuvant Dual HER2-Blockade...
Luz, Paulo; Lopes-Brás, Raquel; Pinho, Inês Soares; Patel, Vanessa; Esperança-Martins, Miguel; Gonçalves, Lisa; Gonçalves, Joana; Freitas, RitaPurpose: Neoadjuvant systemic therapy with dual HER2-blockade, trastuzumab and pertuzumab, combined with chemotherapy has become a standard approach in patients with HER2-positive (HER2+) breast cancer (BC). However, the variability in treatment outcomes, such as pathological complete response (pCR) or relapse rates, underscores the need to identify predictive factors to optimize therapeutic strategies. This st...
Anthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ b...
Pinho, Inês Soares de; Luz, Paulo; Alves, Lucy; Brás, Raquel Lopes; Patel, Vanessa; Martins, Miguel Esperança; Gonçalves, Lisa; Freitas, RitasDeescalation strategies omitting anthracyclines (AC) have been explored in early human epidermal growth factor receptor 2-positive breast cancer (HER2+ EBC), showing similar efcacy regarding pathological complete response (pCR) and long-term outcomes as AC-containing regimens. The standard treatment for this tumor subtype is based on chemotherapy and dual HER2 blockade with trastuzumab and pertuzumab, with AC-c...